Cargando…
Adjuvant effect of Chakshushya Rasayana with beta-blocker eye drops in the management of progressive glaucomatous optic neuropathy: An open-label randomized controlled trial
INTRODUCTION: Primary open angle glaucoma is an insidious and chronic vision-threatening eye ailment due to neuro-retino-optic nerve degeneration, which may be due to the raised intraocular pressure (IOP) or due to independent factors. Management of glaucoma is mainly concentrated on lowering IOP th...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5688835/ https://www.ncbi.nlm.nih.gov/pubmed/29200751 http://dx.doi.org/10.4103/ayu.AYU_30_16 |
_version_ | 1783279252128399360 |
---|---|
author | Dhiman, K. S. Adhoor, Veeranagouda S. Agarwal, Riju Mehta, Amit J. |
author_facet | Dhiman, K. S. Adhoor, Veeranagouda S. Agarwal, Riju Mehta, Amit J. |
author_sort | Dhiman, K. S. |
collection | PubMed |
description | INTRODUCTION: Primary open angle glaucoma is an insidious and chronic vision-threatening eye ailment due to neuro-retino-optic nerve degeneration, which may be due to the raised intraocular pressure (IOP) or due to independent factors. Management of glaucoma is mainly concentrated on lowering IOP that requires lifetime topical medication, different ocular medicaments for lowering of IOP, and surgical interventions, but it has its own limitations to control the progression of glaucomatous optic neuropathy (GON), and this is the reason behind the use of alternative neuroprotective adjuvants. AIM: To evaluate the neuroprotective effect of Ayurvedic line of management of progressive GON. MATERIALS AND METHODS: Ingredients of trial drug Vara Fort powder (Chakshushya Rasayana) were procured from the Institute Pharmacy, except Swarnamakshika Bhasma, which was purchased from Dhootapapeshwar Pharmaceuticals. The patients fulfilling inclusion criteria, attending outpatient and inpatient departments, irrespective of their sex, race, religion, occupation, etc., were selected and divided into two groups with open-labeled randomization. In Group A, in addition to betaxolol (0.1%) or timolol (0.5%) (non-iobrim), Chakshushya Rasayana 6 g/day orally with Triphala Ghrita and honey along with Koshtha-Shuddhi (body-microchannel clearing treatment) protocol was tried. Nasya (oleation through nasal route) with Jeevantyadi Taila and Tarpana (eye satiation) with Go-Ghrita were also performed. In Group B (control), brimonidine (iobrim) 0.2% eye drop was used for 3 months. RESULTS: Significant improvement was observed in subjective parameters in Group A such as blurred vision, frequent change of presbyopic glasses, and delayed dark adaptation. CONCLUSION: Chakshushya Rasayana, if administered in a systematic approach along with a modern topical betaxolol or timolol eye drops, has a definite role in improving the lost retinal sensitivity as much as up to 12 dB in 3 months duration. |
format | Online Article Text |
id | pubmed-5688835 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Medknow Publications & Media Pvt Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-56888352017-12-01 Adjuvant effect of Chakshushya Rasayana with beta-blocker eye drops in the management of progressive glaucomatous optic neuropathy: An open-label randomized controlled trial Dhiman, K. S. Adhoor, Veeranagouda S. Agarwal, Riju Mehta, Amit J. Ayu Original Article INTRODUCTION: Primary open angle glaucoma is an insidious and chronic vision-threatening eye ailment due to neuro-retino-optic nerve degeneration, which may be due to the raised intraocular pressure (IOP) or due to independent factors. Management of glaucoma is mainly concentrated on lowering IOP that requires lifetime topical medication, different ocular medicaments for lowering of IOP, and surgical interventions, but it has its own limitations to control the progression of glaucomatous optic neuropathy (GON), and this is the reason behind the use of alternative neuroprotective adjuvants. AIM: To evaluate the neuroprotective effect of Ayurvedic line of management of progressive GON. MATERIALS AND METHODS: Ingredients of trial drug Vara Fort powder (Chakshushya Rasayana) were procured from the Institute Pharmacy, except Swarnamakshika Bhasma, which was purchased from Dhootapapeshwar Pharmaceuticals. The patients fulfilling inclusion criteria, attending outpatient and inpatient departments, irrespective of their sex, race, religion, occupation, etc., were selected and divided into two groups with open-labeled randomization. In Group A, in addition to betaxolol (0.1%) or timolol (0.5%) (non-iobrim), Chakshushya Rasayana 6 g/day orally with Triphala Ghrita and honey along with Koshtha-Shuddhi (body-microchannel clearing treatment) protocol was tried. Nasya (oleation through nasal route) with Jeevantyadi Taila and Tarpana (eye satiation) with Go-Ghrita were also performed. In Group B (control), brimonidine (iobrim) 0.2% eye drop was used for 3 months. RESULTS: Significant improvement was observed in subjective parameters in Group A such as blurred vision, frequent change of presbyopic glasses, and delayed dark adaptation. CONCLUSION: Chakshushya Rasayana, if administered in a systematic approach along with a modern topical betaxolol or timolol eye drops, has a definite role in improving the lost retinal sensitivity as much as up to 12 dB in 3 months duration. Medknow Publications & Media Pvt Ltd 2016 /pmc/articles/PMC5688835/ /pubmed/29200751 http://dx.doi.org/10.4103/ayu.AYU_30_16 Text en Copyright: © 2017 AYU (An International Quarterly Journal of Research in Ayurveda) http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms. |
spellingShingle | Original Article Dhiman, K. S. Adhoor, Veeranagouda S. Agarwal, Riju Mehta, Amit J. Adjuvant effect of Chakshushya Rasayana with beta-blocker eye drops in the management of progressive glaucomatous optic neuropathy: An open-label randomized controlled trial |
title | Adjuvant effect of Chakshushya Rasayana with beta-blocker eye drops in the management of progressive glaucomatous optic neuropathy: An open-label randomized controlled trial |
title_full | Adjuvant effect of Chakshushya Rasayana with beta-blocker eye drops in the management of progressive glaucomatous optic neuropathy: An open-label randomized controlled trial |
title_fullStr | Adjuvant effect of Chakshushya Rasayana with beta-blocker eye drops in the management of progressive glaucomatous optic neuropathy: An open-label randomized controlled trial |
title_full_unstemmed | Adjuvant effect of Chakshushya Rasayana with beta-blocker eye drops in the management of progressive glaucomatous optic neuropathy: An open-label randomized controlled trial |
title_short | Adjuvant effect of Chakshushya Rasayana with beta-blocker eye drops in the management of progressive glaucomatous optic neuropathy: An open-label randomized controlled trial |
title_sort | adjuvant effect of chakshushya rasayana with beta-blocker eye drops in the management of progressive glaucomatous optic neuropathy: an open-label randomized controlled trial |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5688835/ https://www.ncbi.nlm.nih.gov/pubmed/29200751 http://dx.doi.org/10.4103/ayu.AYU_30_16 |
work_keys_str_mv | AT dhimanks adjuvanteffectofchakshushyarasayanawithbetablockereyedropsinthemanagementofprogressiveglaucomatousopticneuropathyanopenlabelrandomizedcontrolledtrial AT adhoorveeranagoudas adjuvanteffectofchakshushyarasayanawithbetablockereyedropsinthemanagementofprogressiveglaucomatousopticneuropathyanopenlabelrandomizedcontrolledtrial AT agarwalriju adjuvanteffectofchakshushyarasayanawithbetablockereyedropsinthemanagementofprogressiveglaucomatousopticneuropathyanopenlabelrandomizedcontrolledtrial AT mehtaamitj adjuvanteffectofchakshushyarasayanawithbetablockereyedropsinthemanagementofprogressiveglaucomatousopticneuropathyanopenlabelrandomizedcontrolledtrial |